Spotlight on Internal Medicine

Credits: 1.00 CME / CNE
CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV
Matthew Feinstein, MD
American Heart Association

CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV

Start

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: June 28, 2017
Expires: June 28, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) State the CDC/USPSTF recommendation for universal opt-out HIV testing 2) Discuss preventive approaches to reduce risk of ASCVD in patients infected with HIV 3) Recognize the challenge of predicting cardiovascular risk in patients who are HIV-positive 4) Examine the treatment of ASCVD in patients who are HIV-positive

Activity Description

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Additionally, the program reviews epidemiologic patterns in HIV and the relevance of these for understanding the scope of CVD among HIV-infected individuals. Important concepts related to HIV screening and prevention, as well as CVD screening and prevention will be discussed; including new developments and existing barriers regarding CVD treatment for HIV-infected individuals will be reviewed. The activity uses a case-based format interspersed with didactic training to bridge the gap between theory and practice for practitioners caring for HIV-infected individuals.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - Presentation of Case Studies: Reducing Cardiovascular Risk in Patients with HIV

15 minutes – Q & A

Presenters

Matthew J. Feinstein, MD
Assistant Professor of Medicine (Cardiology) and Preventive Medicine
Northwestern Medicine
Feinberg School of Medicine
Chicago, IL


David G. Weismiller, MD, ScM, FAAFP
Professor of Family Medicine
University of Nevada, Las Vegas
School of Medicine,
Las Vegas, NV


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 06/28/2017

TERMINATION DATE: 06/28/2020

LAST REVIEW DATE: June 2017

JOINT ACCREDITATION TERM: 06/28/2017 – 06/28/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/28/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: June 28, 2017
Expires: June 28, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) State the CDC/USPSTF recommendation for universal opt-out HIV testing 2) Discuss preventive approaches to reduce risk of ASCVD in patients infected with HIV 3) Recognize the challenge of predicting cardiovascular risk in patients who are HIV-positive 4) Examine the treatment of ASCVD in patients who are HIV-positive

Activity Description

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Additionally, the program reviews epidemiologic patterns in HIV and the relevance of these for understanding the scope of CVD among HIV-infected individuals. Important concepts related to HIV screening and prevention, as well as CVD screening and prevention will be discussed; including new developments and existing barriers regarding CVD treatment for HIV-infected individuals will be reviewed. The activity uses a case-based format interspersed with didactic training to bridge the gap between theory and practice for practitioners caring for HIV-infected individuals.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - Presentation of Case Studies: Reducing Cardiovascular Risk in Patients with HIV

15 minutes – Q & A

Presenters

Matthew J. Feinstein, MD
Assistant Professor of Medicine (Cardiology) and Preventive Medicine
Northwestern Medicine
Feinberg School of Medicine
Chicago, IL


David G. Weismiller, MD, ScM, FAAFP
Professor of Family Medicine
University of Nevada, Las Vegas
School of Medicine,
Las Vegas, NV


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 06/28/2017

TERMINATION DATE: 06/28/2020

LAST REVIEW DATE: June 2017

JOINT ACCREDITATION TERM: 06/28/2017 – 06/28/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/28/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Internal Medicine Presentations

0.75 CME
AKH Inc., Advancing Knowledge in Healthcare
Addressing Real-World Practice Gaps in the Management of RA

Addressing Real-World Practice Gaps in the Management of RA

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: September 30, 2019
Expires: September 29, 2020
45 minutes to complete

Accredited By

Advancing Knowledge in Healthcare (AKH, Inc.)

Target Audience

This educational activity is designed for rheumatology healthcare professionals who manage patients with rheumatoid arthritis (RA).

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe involvement of the IL-6 signaling pathway in the pathophysiology, extra-articular symptomology, and associated comorbidities of rheumatoid arthritis (RA), and the role of cytokine-targeted therapy in the treatment of RA 
  • Incorporate validated and guideline-recommended RA disease activity monitoring to guide appropriate management of patients 
  • Use a treat-to-target approach for managing RA that personalizes therapy by cycling or switching treatment options in nonresponsive patients, and takes into account data for new and emerging biologic and targeted synthetic DMARDs 
  • Incorporate patient preferences, shared decision making, and patient education into the management plan for patients with RA 

Activity Description

Is a JAK inhibitor an oral IL-6 inhibitor? Is there a typical “TNFi-patient” versus an “IL-6i patient?” How do IL-6 inhibitors affect mood if they don’t cross the blood-brain barrier? We’ve sourced some of the most pressing questions about rheumatoid arthritis (RA) from leaders around the world, and then brought them together to discuss them. We’ve also asked a patient with RA about her experience with the disease and its treatment. In this activity, we put their expert opinion against a patient’s true story. Will they match up?

Statement of Educational Need

Suboptimal management of patients with rheumatoid arthritis (RA) results in disability, inability to work, and substantial direct and indirect cost burden. Outcomes data from previous RA programs and from the literature indicate that despite the fact that effective use of disease-modifying antirheumatic drugs (DMARDs) greatly reduces the potential for joint destruction, systemic immune effects, and disability, rheumatology providers are not effectively utilizing DMARDs, switching drugs when appropriate, utilizing appropriate monitoring tools, using effective SDM strategies to optimize care, nor effectively selecting newer agents when making treatment decisions.

Faculty

>Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair)
Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair)
Arthritis Research UK Professor, Rheumatology  
Director, NIHR Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds Institute of Rheumatic and Musculoskeletal Medicine
University of Leeds
Leeds, UK


Leonard H. Calabrese, DO
Leonard H. Calabrese, DO
Professor of Medicine, Cleveland Clinic Lerner College of Medicine  
Case Western Reserve University
Vice Chairman, Department of Rheumatic and Immunological Diseases  
R. J. Fasenmyer Chair of Clinical Immunology  
Cleveland Clinic 
Cleveland, OH


Ernest Choy, MD, FRCP
Ernest Choy, MD, FRCP
Professor, Head of Rheumatology and Translational Research  
Division of Infection and Immunity  
Director, Arthritis Research UK CREATE Centre and Welsh Arthritis Research Network (WARN)  
Cardiff University School of Medicine  
Cardiff, UK


Conflict of Interest Policy/ Disclosure Statement

It is the policy of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC, to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Leonard H. Calabrese, DO, has affiliations with AbbVie, Amgen, BMS, Crescendo, Genentech, Gilead, GSK, Horizon, Janssen, Lily, Pfizer, Sanofi-Genzyme, UCB (Consultant); AbbVie, BMS, Genentech, Horizon, Janssen, Lily, Sanofi (Speakers Bureau).
  • Ernest Choy, MD, FRCP, has affiliations with Bio-Cancer, Biogen, Novartis, Novimmune, Pfizer, Roche, Sanofi, UCB (Contracted Research); AbbVie, Amgen, Biogen, Chugai Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Roche, R-Pharm, Sanofi (Consultant); Amgen, BMS, Boehringer Ingelheim, Chugai Pharma, Eli Lilly, Hospira, MSD, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis, UCB (Speakers Bureau).
  • Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair), has affiliations with AbbVie, Amgen, BMS, Gilead, Lilly, MSD, Novartis, Pfizer, Samsung, Sanofi (Consultant).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI Medical Education, LLC

  • Lobna Eldasher, PharmD, has no affiliations with commercial interests to disclose.
  • Sharon Powell has no affiliations with commercial interests to disclose.

 AKH Staff and Planners

  • Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has no affiliations with commercial interests to disclose.
  • Patricia Brignoni, AKH, Director of Operations, has disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test and evaluation.

Physicians and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This educational activity is supported by an independent medical educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: September 30, 2019
Expires: September 29, 2020
45 minutes to complete

Accredited By

Advancing Knowledge in Healthcare (AKH, Inc.)

Target Audience

This educational activity is designed for rheumatology healthcare professionals who manage patients with rheumatoid arthritis (RA).

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe involvement of the IL-6 signaling pathway in the pathophysiology, extra-articular symptomology, and associated comorbidities of rheumatoid arthritis (RA), and the role of cytokine-targeted therapy in the treatment of RA 
  • Incorporate validated and guideline-recommended RA disease activity monitoring to guide appropriate management of patients 
  • Use a treat-to-target approach for managing RA that personalizes therapy by cycling or switching treatment options in nonresponsive patients, and takes into account data for new and emerging biologic and targeted synthetic DMARDs 
  • Incorporate patient preferences, shared decision making, and patient education into the management plan for patients with RA 

Activity Description

Is a JAK inhibitor an oral IL-6 inhibitor? Is there a typical “TNFi-patient” versus an “IL-6i patient?” How do IL-6 inhibitors affect mood if they don’t cross the blood-brain barrier? We’ve sourced some of the most pressing questions about rheumatoid arthritis (RA) from leaders around the world, and then brought them together to discuss them. We’ve also asked a patient with RA about her experience with the disease and its treatment. In this activity, we put their expert opinion against a patient’s true story. Will they match up?

Statement of Educational Need

Suboptimal management of patients with rheumatoid arthritis (RA) results in disability, inability to work, and substantial direct and indirect cost burden. Outcomes data from previous RA programs and from the literature indicate that despite the fact that effective use of disease-modifying antirheumatic drugs (DMARDs) greatly reduces the potential for joint destruction, systemic immune effects, and disability, rheumatology providers are not effectively utilizing DMARDs, switching drugs when appropriate, utilizing appropriate monitoring tools, using effective SDM strategies to optimize care, nor effectively selecting newer agents when making treatment decisions.

Faculty

>Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair)
Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair)
Arthritis Research UK Professor, Rheumatology  
Director, NIHR Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds Institute of Rheumatic and Musculoskeletal Medicine
University of Leeds
Leeds, UK


Leonard H. Calabrese, DO
Leonard H. Calabrese, DO
Professor of Medicine, Cleveland Clinic Lerner College of Medicine  
Case Western Reserve University
Vice Chairman, Department of Rheumatic and Immunological Diseases  
R. J. Fasenmyer Chair of Clinical Immunology  
Cleveland Clinic 
Cleveland, OH


Ernest Choy, MD, FRCP
Ernest Choy, MD, FRCP
Professor, Head of Rheumatology and Translational Research  
Division of Infection and Immunity  
Director, Arthritis Research UK CREATE Centre and Welsh Arthritis Research Network (WARN)  
Cardiff University School of Medicine  
Cardiff, UK


Conflict of Interest Policy/ Disclosure Statement

It is the policy of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC, to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Leonard H. Calabrese, DO, has affiliations with AbbVie, Amgen, BMS, Crescendo, Genentech, Gilead, GSK, Horizon, Janssen, Lily, Pfizer, Sanofi-Genzyme, UCB (Consultant); AbbVie, BMS, Genentech, Horizon, Janssen, Lily, Sanofi (Speakers Bureau).
  • Ernest Choy, MD, FRCP, has affiliations with Bio-Cancer, Biogen, Novartis, Novimmune, Pfizer, Roche, Sanofi, UCB (Contracted Research); AbbVie, Amgen, Biogen, Chugai Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Roche, R-Pharm, Sanofi (Consultant); Amgen, BMS, Boehringer Ingelheim, Chugai Pharma, Eli Lilly, Hospira, MSD, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis, UCB (Speakers Bureau).
  • Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair), has affiliations with AbbVie, Amgen, BMS, Gilead, Lilly, MSD, Novartis, Pfizer, Samsung, Sanofi (Consultant).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI Medical Education, LLC

  • Lobna Eldasher, PharmD, has no affiliations with commercial interests to disclose.
  • Sharon Powell has no affiliations with commercial interests to disclose.

 AKH Staff and Planners

  • Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has no affiliations with commercial interests to disclose.
  • Patricia Brignoni, AKH, Director of Operations, has disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test and evaluation.

Physicians and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This educational activity is supported by an independent medical educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

1.00 CE
Vindico
Improving Outcomes in Chronic COPD Care

Improving Outcomes in Chronic COPD Care

Start

Activity Details

Free CE
0.75 Contact Hour(s)
Released: August 26, 2019
Expires: August 25, 2020
45 minutes to complete

Provided By

This continuing education activity is provided by Vindico Medical Education.

Statement of Commercial Support

This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply American Nurses Credentialing Center (ANCC) Commission on Accreditation endorsement of any commercial products.

Target Audience

The intended audience for this activity is long-term care directors of nursing, advance practice nurses, nurses, and other health care professionals involved in the management of patients with chronic obstructive pulmonary disease (COPD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate new GOLD guidelines into practice for the assessment and management of patients with COPD.
  • Assess current evidence about the use of combined therapy in the treatment of patients with COPD.
  • Apply new evidence about the use of nebulizers and inhalers to improve the efficacy of inhaled COPD medications.

Activity Description

This continuing education (CE) activity is based on the slides and lectures presented by the faculty at the live program, “Improving Outcomes in Chronic COPD Care,” on June 5, 2019, at the Planet Hollywood Resort and Casino in Las Vegas, NV.

Statement of Educational Need

Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality worldwide. Due to the progressive nature of COPD, a significant number of diagnosed individuals will be admitted to a long-term care facility during their disease. Reports such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, which was extensively revised in 2017 and updated in 2019, continue to provide guidance regarding optimal diagnostic and treatment algorithms for COPD, while new and emerging therapies and devices look to provide a more personalized therapeutic approach. Integration of these recommendations and therapeutic approaches into current management paradigms has the potential to benefit patients with COPD. Within this educational activity, a panel of experts in the field will evaluate COPD in long-term care facilities, assess therapies and delivery devices for optimal administration of medications, and provide direction to incorporate GOLD guidelines into practice for the enhancement of patient outcomes. The presentation of 2 COPD cases will further provide guidance for the optimal diagnosis and management of patients with COPD.

Agenda

  • Getting With the GOLD in Long-term Care Settings
    Charles Michael Bobbitt MSN, RN, CDONA
  • GOLD Standards in the Treatment of COPD in the Long-term Care Setting
    Albert Riddle, MD, CMD, HMDC
  • COPD Case Challenges
    Daniel Haimowitz, MD, CMD

Activity Chair

Daniel Haimowitz, MD, CMD
Multi-facility Medical Director
Private Practice
Levittown, PA
  • No relevant financial relationships to disclose.


Faculty

Charles Michael Bobbitt, MSN, RN, CDONA
Nursing Faculty
El Centro College
Dallas County Community College District
Dallas, TX
  • Salary (spouse): Johnson & Johnson
    Ownership Interest: Johnson & Johnson


Albert Riddle, MD, CMD, HMDC
President
Riddle Medical LLC
Multi-facility Medical Director
Tarrytown, NY
  • Speakers Bureau: Acadia, Janssen


Nurse Planners report the following relationship(s):
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Charles Michael Bobbitt MSN, RN, CDONA
Salary (spouse): Johnson & Johnson
Ownership Interest: Johnson & Johnson

Conflict of Interest Policy/Disclosure Statement

In accordance with the American Nurses Credentialing Center’s Standards for Commercial Support, all CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CNE activity content over which the individual has control. Relationship information appears above and below.

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Education and Compliance.

Accreditation Statement

Vindico Medical Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education will provide 0.75 contact hours for nurses.

This activity is approved for 0.75 contact hour(s) of continuing education (which includes 0.5 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19083831. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue a Learner-Paced Contact Hour Certificate.

Disclaimer

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CE
0.75 Contact Hour(s)
Released: August 26, 2019
Expires: August 25, 2020
45 minutes to complete

Provided By

This continuing education activity is provided by Vindico Medical Education.

Statement of Commercial Support

This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply American Nurses Credentialing Center (ANCC) Commission on Accreditation endorsement of any commercial products.

Target Audience

The intended audience for this activity is long-term care directors of nursing, advance practice nurses, nurses, and other health care professionals involved in the management of patients with chronic obstructive pulmonary disease (COPD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate new GOLD guidelines into practice for the assessment and management of patients with COPD.
  • Assess current evidence about the use of combined therapy in the treatment of patients with COPD.
  • Apply new evidence about the use of nebulizers and inhalers to improve the efficacy of inhaled COPD medications.

Activity Description

This continuing education (CE) activity is based on the slides and lectures presented by the faculty at the live program, “Improving Outcomes in Chronic COPD Care,” on June 5, 2019, at the Planet Hollywood Resort and Casino in Las Vegas, NV.

Statement of Educational Need

Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality worldwide. Due to the progressive nature of COPD, a significant number of diagnosed individuals will be admitted to a long-term care facility during their disease. Reports such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, which was extensively revised in 2017 and updated in 2019, continue to provide guidance regarding optimal diagnostic and treatment algorithms for COPD, while new and emerging therapies and devices look to provide a more personalized therapeutic approach. Integration of these recommendations and therapeutic approaches into current management paradigms has the potential to benefit patients with COPD. Within this educational activity, a panel of experts in the field will evaluate COPD in long-term care facilities, assess therapies and delivery devices for optimal administration of medications, and provide direction to incorporate GOLD guidelines into practice for the enhancement of patient outcomes. The presentation of 2 COPD cases will further provide guidance for the optimal diagnosis and management of patients with COPD.

Agenda

  • Getting With the GOLD in Long-term Care Settings
    Charles Michael Bobbitt MSN, RN, CDONA
  • GOLD Standards in the Treatment of COPD in the Long-term Care Setting
    Albert Riddle, MD, CMD, HMDC
  • COPD Case Challenges
    Daniel Haimowitz, MD, CMD

Activity Chair

Daniel Haimowitz, MD, CMD
Multi-facility Medical Director
Private Practice
Levittown, PA
  • No relevant financial relationships to disclose.


Faculty

Charles Michael Bobbitt, MSN, RN, CDONA
Nursing Faculty
El Centro College
Dallas County Community College District
Dallas, TX
  • Salary (spouse): Johnson & Johnson
    Ownership Interest: Johnson & Johnson


Albert Riddle, MD, CMD, HMDC
President
Riddle Medical LLC
Multi-facility Medical Director
Tarrytown, NY
  • Speakers Bureau: Acadia, Janssen


Nurse Planners report the following relationship(s):
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Charles Michael Bobbitt MSN, RN, CDONA
Salary (spouse): Johnson & Johnson
Ownership Interest: Johnson & Johnson

Conflict of Interest Policy/Disclosure Statement

In accordance with the American Nurses Credentialing Center’s Standards for Commercial Support, all CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CNE activity content over which the individual has control. Relationship information appears above and below.

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Education and Compliance.

Accreditation Statement

Vindico Medical Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education will provide 0.75 contact hours for nurses.

This activity is approved for 0.75 contact hour(s) of continuing education (which includes 0.5 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19083831. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue a Learner-Paced Contact Hour Certificate.

Disclaimer

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

CME Questions?

Contact us at CME@VindicoCME.com

0.75 CME
Vindico
Improving the Delivery of Immunotherapy for Peanut Allergy Management – Rapid Response From Lisbon

Improving the Delivery of Immunotherapy for Peanut Allergy Management – Rapid Response From Lisbon

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: August 7, 2019
Expires: August 6, 2020
45 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by an educational grant from Aimmune Therapeutics, Inc.

Activity Chair

Ruchi S. Gupta, MD, MPH
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director, Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL
  • Disclosures:
    Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
    Contracted Research: Thermo Fisher Scientific, United Health Group


Faculty

Aikaterini Anagnostou, MD (Hons), MSc, PhD
Associate Professor of Pediatric Allergy
Director, Food Immunotherapy Program
Associate Director, Food Allergy Program
Immunology, Allergy and Rheumatology
Texas Children's Hospital
Baylor College of Medicine
Houston, TX
  • Disclosures:
    Contracted Research (paid to institution): Aimmune


Christina E. Ciaccio, MD, MSc
Associate Professor of Pediatrics
Section Chief
Allergy/Immunology and Pediatric Pulmonology and Sleep Medicine
University of Chicago Medicine
Chicago, IL
  • Disclosures:
    Consulting Fee: Aimmune, Regeneron
    Speakers Bureau: Aimmune
    Contracted Research: Aimmune, Astellas, DBV Technologies, Sanofi


Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, August 7, 2019 to August 6, 2020.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the video, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Overview

The prevalence of food allergy has been increasing, especially among children, with nearly 1 in 13 children in the United States being impacted. Peanut allergy, in particular, has attracted growing attention in recent years as it has become increasingly common. Despite this, there are no approved treatments specifically for food allergy, and standard immunotherapy has limitations. This CME activity will assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management and will feature the most recent data from the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.

Target Audience

The intended audience for the activity is allergists, immunologists, and other health care professionals involved in the management of patients with peanut allergy.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management.
  • Review the potential impact of raising the peanut allergen threshold on patient quality of life and/or the need for emergent care.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: August 7, 2019
Expires: August 6, 2020
45 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by an educational grant from Aimmune Therapeutics, Inc.

Activity Chair

Ruchi S. Gupta, MD, MPH
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director, Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL
  • Disclosures:
    Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
    Contracted Research: Thermo Fisher Scientific, United Health Group


Faculty

Aikaterini Anagnostou, MD (Hons), MSc, PhD
Associate Professor of Pediatric Allergy
Director, Food Immunotherapy Program
Associate Director, Food Allergy Program
Immunology, Allergy and Rheumatology
Texas Children's Hospital
Baylor College of Medicine
Houston, TX
  • Disclosures:
    Contracted Research (paid to institution): Aimmune


Christina E. Ciaccio, MD, MSc
Associate Professor of Pediatrics
Section Chief
Allergy/Immunology and Pediatric Pulmonology and Sleep Medicine
University of Chicago Medicine
Chicago, IL
  • Disclosures:
    Consulting Fee: Aimmune, Regeneron
    Speakers Bureau: Aimmune
    Contracted Research: Aimmune, Astellas, DBV Technologies, Sanofi


Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, August 7, 2019 to August 6, 2020.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the video, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Overview

The prevalence of food allergy has been increasing, especially among children, with nearly 1 in 13 children in the United States being impacted. Peanut allergy, in particular, has attracted growing attention in recent years as it has become increasingly common. Despite this, there are no approved treatments specifically for food allergy, and standard immunotherapy has limitations. This CME activity will assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management and will feature the most recent data from the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.

Target Audience

The intended audience for the activity is allergists, immunologists, and other health care professionals involved in the management of patients with peanut allergy.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management.
  • Review the potential impact of raising the peanut allergen threshold on patient quality of life and/or the need for emergent care.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME
Forefront Collaborative
Rethinking Migraine Treatment: New Therapies Impacting Patient Care

Rethinking Migraine Treatment: New Therapies Impacting Patient Care

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: July 15, 2019
Expires: July 14, 2020
60 minutes to complete

Accredited By

Target Audience

This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
  2. Develop treatment plans in line with standards of practice for acute and preventive management of episodic and chronic migraine.
  3. Discuss unmet patient needs and burden of episodic and chronic migraine.
  4. Analyze safety and efficacy data for emerging therapies in acute and preventive treatment of migraine relative to current standards and clinically meaningful outcomes.

Activity Description

The thinking around both preventive and acute treatment of migraine is undergoing a radical change as new therapies emerge that target varied routes, some specific to known mechanisms of migraine pathophysiology. From new classes of treatment to emerging therapies and neuromodulatory devices, headache specialist and general neurologist, Stewart J. Tepper, MD, and Ana Felix, MD, FAAN, team up to provide a practical update for practicing clinicians on key treatment advances that are transforming migraine care.

Statement of Educational Need

With the recent approvals, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).

Agenda

The New Era of Migraine Treatment
Cases in Episodic and Chronic Migraine

Faculty

Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Ana Felix, MD, FAAN
Neurologist,
Assistant Professor,
Department of Internal Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Inc, Allergan, Alphasights, Amgen, Autonomic Technologies, Inc., Axsome Therapeutics, Cefaly, Charleston Laboratories, Inc., DeepBench, Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, LLC, Magellan Rx Management, Neurolief Ltd., Nordic BioTech, Novartis, Pfizer, Scion Neurostim, LLC, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Inc., Dr. Reddy’s Laboratories, Ltd., electroCore, LLC, eNeura, Neurolief, Novartis, Scion Neurostim, LLC, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies, Inc.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva PharmaceuticalIndustries Ltd.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:

  • Faculty: Ana Felix, MD, FAAN
  • Planner (Forefront Collaborative):Krista Jaworski

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 80%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Content Review Statement

The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions about the Activity

Krista_jaworski@forefrontcollab.com
812-340-4274

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: July 15, 2019
Expires: July 14, 2020
60 minutes to complete

Accredited By

Target Audience

This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
  2. Develop treatment plans in line with standards of practice for acute and preventive management of episodic and chronic migraine.
  3. Discuss unmet patient needs and burden of episodic and chronic migraine.
  4. Analyze safety and efficacy data for emerging therapies in acute and preventive treatment of migraine relative to current standards and clinically meaningful outcomes.

Activity Description

The thinking around both preventive and acute treatment of migraine is undergoing a radical change as new therapies emerge that target varied routes, some specific to known mechanisms of migraine pathophysiology. From new classes of treatment to emerging therapies and neuromodulatory devices, headache specialist and general neurologist, Stewart J. Tepper, MD, and Ana Felix, MD, FAAN, team up to provide a practical update for practicing clinicians on key treatment advances that are transforming migraine care.

Statement of Educational Need

With the recent approvals, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).

Agenda

The New Era of Migraine Treatment
Cases in Episodic and Chronic Migraine

Faculty

Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Ana Felix, MD, FAAN
Neurologist,
Assistant Professor,
Department of Internal Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Inc, Allergan, Alphasights, Amgen, Autonomic Technologies, Inc., Axsome Therapeutics, Cefaly, Charleston Laboratories, Inc., DeepBench, Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, LLC, Magellan Rx Management, Neurolief Ltd., Nordic BioTech, Novartis, Pfizer, Scion Neurostim, LLC, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Inc., Dr. Reddy’s Laboratories, Ltd., electroCore, LLC, eNeura, Neurolief, Novartis, Scion Neurostim, LLC, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies, Inc.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva PharmaceuticalIndustries Ltd.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:

  • Faculty: Ana Felix, MD, FAAN
  • Planner (Forefront Collaborative):Krista Jaworski

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 80%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Content Review Statement

The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions about the Activity

Krista_jaworski@forefrontcollab.com
812-340-4274

1.00 CME
Academy for Continued Healthcare Learning
JAK-STAT-GO: Personalized, Targeted Therapy Options for Your IBD Patients

JAK-STAT-GO: Personalized, Targeted Therapy Options for Your IBD Patients

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: June 27, 2019
Expires: June 27, 2020
60 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, and other allied health care professionals interested in the JAK/STAT signaling pathway and applications to treatment of IBD.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the role of the JAK/STAT signaling pathway in the pathogenesis of IBD and the rationale for inhibition
  • Compare and contrast the cytokine pathways targeted by available and emerging JAK inhibitors in IBD
  • Interpret the clinical trial efficacy and safety data of JAK inhibitors investigated for Crohn’s disease and ulcerative colitis
  • Identify IBD patients who require a change in therapy

Activity Description

How can clinicians know they have current information for improving patients’ IBD outcomes? Expert faculty from the Icahn School of Medicine at Mount Sinai, University of Chicago Medicine and Biological Sciences, and Montefiore Medical Center/Albert Einstein College of Medicine recently led a symposium at Digestive Disease Week® (DDW) 2019 exploring the latest in treat-to-target paradigms, the role of the JAK-STAT pathway, and related research on investigational JAK inhibitors in IBD treatment. Video excerpts from the symposium are available as modules making it easier for the learner to move easily from one excerpt to another. This activity qualifies for QPP Improvement Activity points.

Statement of Educational Need

Clinicians who treat patients with inflammatory disease such as IBD need to be updated on new and emerging therapies that will lead to individualized treatment and improved outcomes. Specifically, clinicians require education surrounding the role of the JAK/STAT signaling pathway in immune mediated diseases, up-to-date knowledge of the efficacy and safety of investigational JAK inhibitors, and the role of new and emerging JAK inhibitors in the treatment paradigm in IBD.

Agenda

Video module highlights includes:

  • What’s New in IBD Care? Choosing Targets and Selecting Therapy
  • The JAK/STAT Signaling Pathway as a Target/Panel Discussion
  • Available Data on the Safety of JAK Inhibition: Rheumatology Experience/Panel Discussion
  • Available and Emerging JAK Inhibitors in IBD: Clinical Trials, Populations, and Safety/Panel Discussion

Faculty

Bruce Sands, MD, MS
Bruce Sands, MD, MS
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY


Joel Pekow, MD
Joel Pekow, MD
Assistant Professor of Medicine, Section of Gastroenterology, Hepatology, and Nutrition
University of Chicago Medicine and Biological Sciences
Chicago, IL


Thomas Ullman, MD
Thomas Ullman, MD
Chief, Division of Gastroenterology
Montefiore Medical Center/Albert Einstein College of Medicine
Bronx, NY


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Bruce Sands, MD, MS, (Chair)
Consulting Agreements: AbbVie, Allergan, Amgen, Inc., Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Celgene, Celltrion Healthcare, F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals, Gilead Sciences, Inc., Ironwood Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Lilly, Otsuka, Pfizer, Inc., Prometheus Laboratories Inc., Salix Pharmaceuticals, Shire, Takeda, Theravance Biopharma R&D, Inc.
Grant/Research Support: Celgene
Honoraria Recipient: Takeda

Joel Pekow, MD, (Faculty)
Advisory Board: Janssen Pharmaceuticals, Inc. and Pfizer, Inc.
Consulting Agreement: Verastem
Grant Support: Takeda and AbbVie

Thomas Ullman, MD, (Faculty)
Advisory Board: Pfizer, Inc.
Honoraria Recipient: Janssen Pharmaceuticals, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Tofacitinib, peficitinib, filgotinib, upadacitinib, and other JAK inhibitors under investigation for IBD

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MIPS Improvement Activity

Completion of this activity including the pre/posttest and follow-up assignments qualifies as a medium weight MIPS improvement activity under MACRA, and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive a certificate of completion after completing the follow-up survey.

Instructions for Receiving Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 65% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions about the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: June 27, 2019
Expires: June 27, 2020
60 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, and other allied health care professionals interested in the JAK/STAT signaling pathway and applications to treatment of IBD.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the role of the JAK/STAT signaling pathway in the pathogenesis of IBD and the rationale for inhibition
  • Compare and contrast the cytokine pathways targeted by available and emerging JAK inhibitors in IBD
  • Interpret the clinical trial efficacy and safety data of JAK inhibitors investigated for Crohn’s disease and ulcerative colitis
  • Identify IBD patients who require a change in therapy

Activity Description

How can clinicians know they have current information for improving patients’ IBD outcomes? Expert faculty from the Icahn School of Medicine at Mount Sinai, University of Chicago Medicine and Biological Sciences, and Montefiore Medical Center/Albert Einstein College of Medicine recently led a symposium at Digestive Disease Week® (DDW) 2019 exploring the latest in treat-to-target paradigms, the role of the JAK-STAT pathway, and related research on investigational JAK inhibitors in IBD treatment. Video excerpts from the symposium are available as modules making it easier for the learner to move easily from one excerpt to another. This activity qualifies for QPP Improvement Activity points.

Statement of Educational Need

Clinicians who treat patients with inflammatory disease such as IBD need to be updated on new and emerging therapies that will lead to individualized treatment and improved outcomes. Specifically, clinicians require education surrounding the role of the JAK/STAT signaling pathway in immune mediated diseases, up-to-date knowledge of the efficacy and safety of investigational JAK inhibitors, and the role of new and emerging JAK inhibitors in the treatment paradigm in IBD.

Agenda

Video module highlights includes:

  • What’s New in IBD Care? Choosing Targets and Selecting Therapy
  • The JAK/STAT Signaling Pathway as a Target/Panel Discussion
  • Available Data on the Safety of JAK Inhibition: Rheumatology Experience/Panel Discussion
  • Available and Emerging JAK Inhibitors in IBD: Clinical Trials, Populations, and Safety/Panel Discussion

Faculty

Bruce Sands, MD, MS
Bruce Sands, MD, MS
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY


Joel Pekow, MD
Joel Pekow, MD
Assistant Professor of Medicine, Section of Gastroenterology, Hepatology, and Nutrition
University of Chicago Medicine and Biological Sciences
Chicago, IL


Thomas Ullman, MD
Thomas Ullman, MD
Chief, Division of Gastroenterology
Montefiore Medical Center/Albert Einstein College of Medicine
Bronx, NY


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Bruce Sands, MD, MS, (Chair)
Consulting Agreements: AbbVie, Allergan, Amgen, Inc., Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Celgene, Celltrion Healthcare, F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals, Gilead Sciences, Inc., Ironwood Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Lilly, Otsuka, Pfizer, Inc., Prometheus Laboratories Inc., Salix Pharmaceuticals, Shire, Takeda, Theravance Biopharma R&D, Inc.
Grant/Research Support: Celgene
Honoraria Recipient: Takeda

Joel Pekow, MD, (Faculty)
Advisory Board: Janssen Pharmaceuticals, Inc. and Pfizer, Inc.
Consulting Agreement: Verastem
Grant Support: Takeda and AbbVie

Thomas Ullman, MD, (Faculty)
Advisory Board: Pfizer, Inc.
Honoraria Recipient: Janssen Pharmaceuticals, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Tofacitinib, peficitinib, filgotinib, upadacitinib, and other JAK inhibitors under investigation for IBD

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MIPS Improvement Activity

Completion of this activity including the pre/posttest and follow-up assignments qualifies as a medium weight MIPS improvement activity under MACRA, and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive a certificate of completion after completing the follow-up survey.

Instructions for Receiving Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 65% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions about the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org

0.75 CME
Integrity Continuing Education, Inc.
Ensuring Early Diagnosis and Targeting Treatment to Remission in Patients with Rheumatoid Arthritis: Recommendations for Primary Care Clinicians

Ensuring Early Diagnosis and Targeting Treatment to Remission in Patients with Rheumatoid Arthritis: Recommendations for Primary Care Clinicians

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: June 21, 2019
Expires: June 21, 2020
45 minutes to complete

Provided By

Target Audience

This educational activity has been designed for primary care clinicians, physician assistants, and nurse practitioners involved in the management of patients with rheumatoid arthritis (RA).

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Implement screening to improve early diagnosis of RA
  • Apply a treat-to-target approach that is consistent with current guideline recommendations for RA management
  • Describe the mechanisms of action of approved targeted therapies for the treatment of RA
  • Utilize strategies for early identification of important comorbidities and their management in patients with RA

Activity Description

Simulation Activity

Statement of Educational Need

RA imposes a significant healthcare burden in the US and many affected individuals continue to report poor quality of life despite ongoing treatment. Although numerous therapies are currently available, deficits in knowledge regarding their mechanisms of action and appropriate use, as well as inadequate compliance with published guidelines, remain persistent among clinicians. Additionally, many clinicians report a lack of awareness regarding the increase in risk for certain comorbidities and how to approach their management in patients with RA. Collectively, these observations indicate an important need for additional education regarding the early diagnosis of RA, the efficacy and safety of targeted therapies for treatment, and the implementation of a treat-to-target approach to disease management that takes into consideration the presence of comorbid conditions. With this in mind, this program has been developed to aid primary care clinicians, who are often at the frontline of care for individuals with RA, in acquiring the knowledge and skills required to improve the health outcomes of these patients.

Faculty

Roy Fleischmann, MD
Roy Fleischmann, MD
Clinical Professor of Medicine
Department of Medicine
University of Texas
Southwestern Medical Center
Dallas, Texas


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Roy Fleischmann, MD
Advisory Boards: AbbVie, Eli Lilly & Company, Pfizer
Contracted Research: AbbVie, Eli Lilly & Company, Gilead, Pfizer

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 21, 2019 through June 21, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: June 21, 2019
Expires: June 21, 2020
45 minutes to complete

Provided By

Target Audience

This educational activity has been designed for primary care clinicians, physician assistants, and nurse practitioners involved in the management of patients with rheumatoid arthritis (RA).

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Implement screening to improve early diagnosis of RA
  • Apply a treat-to-target approach that is consistent with current guideline recommendations for RA management
  • Describe the mechanisms of action of approved targeted therapies for the treatment of RA
  • Utilize strategies for early identification of important comorbidities and their management in patients with RA

Activity Description

Simulation Activity

Statement of Educational Need

RA imposes a significant healthcare burden in the US and many affected individuals continue to report poor quality of life despite ongoing treatment. Although numerous therapies are currently available, deficits in knowledge regarding their mechanisms of action and appropriate use, as well as inadequate compliance with published guidelines, remain persistent among clinicians. Additionally, many clinicians report a lack of awareness regarding the increase in risk for certain comorbidities and how to approach their management in patients with RA. Collectively, these observations indicate an important need for additional education regarding the early diagnosis of RA, the efficacy and safety of targeted therapies for treatment, and the implementation of a treat-to-target approach to disease management that takes into consideration the presence of comorbid conditions. With this in mind, this program has been developed to aid primary care clinicians, who are often at the frontline of care for individuals with RA, in acquiring the knowledge and skills required to improve the health outcomes of these patients.

Faculty

Roy Fleischmann, MD
Roy Fleischmann, MD
Clinical Professor of Medicine
Department of Medicine
University of Texas
Southwestern Medical Center
Dallas, Texas


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Roy Fleischmann, MD
Advisory Boards: AbbVie, Eli Lilly & Company, Pfizer
Contracted Research: AbbVie, Eli Lilly & Company, Gilead, Pfizer

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 21, 2019 through June 21, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

0.50 CME
Integrity Continuing Education, Inc.
Enhancing the Patient-Provider Connection: Practical Strategies for Improving Outcomes in Obesity Management

Enhancing the Patient-Provider Connection: Practical Strategies for Improving Outcomes in Obesity Management

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credits
Released: June 6, 2019
Expires: June 6, 2020
30 minutes to complete

Provided By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Analyze regional and ethnic disparities in obesity
  • Address patients with obesity with sensitivity and a greater understanding of this disorder’s causes, challenges, and treatments
  • Apply current practice guidelines to optimize screening, diagnosis, and treatment
  • Implement proven communication strategies, such as The 5 A’s of Obesity Counseling, to effectively engage patients in weight loss discussion
  • Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss

Activity Description

The U.S. Preventative Services Task Force and the American Academy of Pediatrics recommend that physicians screen patients for obesity and practice counseling interventions to achieve modest (4%-8%) weight loss. Despite this, physicians frequently do not document obesity, counsel, or initiate therapy for weight loss. Medically-managed weight loss may provide the safest and most effective means to initial weight loss and weight loss maintenance over time. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of health professionals. This program will improve family physicians’ skills and confidence in weight loss counseling and treatment while also discussing geographic, ethnic, and racial disparities.

Statement of Educational Need

In this CME activity, you will view video clips of unhelpful and helpful clinicians and expert faculty commentary to learn how to effectively and appropriately screen, diagnose, and treat patients with obesity.

Faculty

Deborah Bade Horn, DO, MPH
Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Bausch Health/Valeant Pharmaceuticals International; Novo Nordisk, Inc.
Speakers’ Bureau: Novo Nordisk, Inc.
Contracted Research: Novo Nordisk, Inc.

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 6, 2019 through June 6, 2020 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk Inc.

Activity Details

Free CME
0.50 AMA PRA Category 1 Credits
Released: June 6, 2019
Expires: June 6, 2020
30 minutes to complete

Provided By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Analyze regional and ethnic disparities in obesity
  • Address patients with obesity with sensitivity and a greater understanding of this disorder’s causes, challenges, and treatments
  • Apply current practice guidelines to optimize screening, diagnosis, and treatment
  • Implement proven communication strategies, such as The 5 A’s of Obesity Counseling, to effectively engage patients in weight loss discussion
  • Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss

Activity Description

The U.S. Preventative Services Task Force and the American Academy of Pediatrics recommend that physicians screen patients for obesity and practice counseling interventions to achieve modest (4%-8%) weight loss. Despite this, physicians frequently do not document obesity, counsel, or initiate therapy for weight loss. Medically-managed weight loss may provide the safest and most effective means to initial weight loss and weight loss maintenance over time. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of health professionals. This program will improve family physicians’ skills and confidence in weight loss counseling and treatment while also discussing geographic, ethnic, and racial disparities.

Statement of Educational Need

In this CME activity, you will view video clips of unhelpful and helpful clinicians and expert faculty commentary to learn how to effectively and appropriately screen, diagnose, and treat patients with obesity.

Faculty

Deborah Bade Horn, DO, MPH
Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Bausch Health/Valeant Pharmaceuticals International; Novo Nordisk, Inc.
Speakers’ Bureau: Novo Nordisk, Inc.
Contracted Research: Novo Nordisk, Inc.

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 6, 2019 through June 6, 2020 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk Inc.

0.50 CME
Integrity Continuing Education, Inc.
Striking a Balance: Exploring the Role of SGLT Inhibitors in the Treatment of Type 1 Diabetes

Striking a Balance: Exploring the Role of SGLT Inhibitors in the Treatment of Type 1 Diabetes

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: May 10, 2019
Expires: May 10, 2020
30 minutes to complete

Provided By

Target Audience

This program is intended for endocrinologists and healthcare providers that manage patients with T1DM.

Learning Objectives

  • Explain the relationship between glycemic control and micro/macrovascular complications in patients with T1DM
  • Apply current evidence-based strategies to achieve glycemic control while minimizing common side effects of insulin therapy
  • Discuss the evolving role of SGLT inhibitors with insulin in patients with T1DM

Activity Description

Insulin is the staple of therapy in patients with T1DM; however, sodium-glucose cotransporter (SGLT) inhibitors have been investigated as a potential adjunct therapy to improve glycemic outcomes while minimizing adverse events in these patients. To be best prepared to achieve glycemic goals in patients with T1DM, HCPs must be kept up-to-date on new evidence from the medical literature and clinical practice, including the relationship between glycemic control and micro/macrovascular complications, strategies for achieving effective glycemic control, and recent data on the use of SGLT inhibitors alongside insulin to improve outcomes.

Faculty

John Buse, MD, PhD
Verne S. Caviness Distinguished Professor
Director, Diabetes Center
Chief, Division of Endocrinology
Executive Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, North Carolina


Anne L. Peters, MD
Director, USC Clinical Diabetes Program
Professor of Clinical Medicine
University of Southern California
Los Angeles, California


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education is committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

John Buse, MD, PhD
Consultant: Neurimmune AG
Research: Novo Nordisk, Sanofi, vTv Therapeutics
Ownership Interest: Mellitus Health, PhaseBio, Stability Health

Anne L. Peters, MD
Consultant: Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Company, Lexicon, Livongo, Medscape, Merck, Novo Nordisk, OptumHealth, Sanofi
Speakers’ Bureaus: Novo Nordisk, Sanofi
Research: AstraZeneca, Dexcom, Mannkind
Stock Options: Mellitus Health, Omada Health, Stability Health

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of May 10, 2019 through May 10, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

Statement of Commercial Support

This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: May 10, 2019
Expires: May 10, 2020
30 minutes to complete

Provided By

Target Audience

This program is intended for endocrinologists and healthcare providers that manage patients with T1DM.

Learning Objectives

  • Explain the relationship between glycemic control and micro/macrovascular complications in patients with T1DM
  • Apply current evidence-based strategies to achieve glycemic control while minimizing common side effects of insulin therapy
  • Discuss the evolving role of SGLT inhibitors with insulin in patients with T1DM

Activity Description

Insulin is the staple of therapy in patients with T1DM; however, sodium-glucose cotransporter (SGLT) inhibitors have been investigated as a potential adjunct therapy to improve glycemic outcomes while minimizing adverse events in these patients. To be best prepared to achieve glycemic goals in patients with T1DM, HCPs must be kept up-to-date on new evidence from the medical literature and clinical practice, including the relationship between glycemic control and micro/macrovascular complications, strategies for achieving effective glycemic control, and recent data on the use of SGLT inhibitors alongside insulin to improve outcomes.

Faculty

John Buse, MD, PhD
Verne S. Caviness Distinguished Professor
Director, Diabetes Center
Chief, Division of Endocrinology
Executive Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, North Carolina


Anne L. Peters, MD
Director, USC Clinical Diabetes Program
Professor of Clinical Medicine
University of Southern California
Los Angeles, California


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education is committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

John Buse, MD, PhD
Consultant: Neurimmune AG
Research: Novo Nordisk, Sanofi, vTv Therapeutics
Ownership Interest: Mellitus Health, PhaseBio, Stability Health

Anne L. Peters, MD
Consultant: Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Company, Lexicon, Livongo, Medscape, Merck, Novo Nordisk, OptumHealth, Sanofi
Speakers’ Bureaus: Novo Nordisk, Sanofi
Research: AstraZeneca, Dexcom, Mannkind
Stock Options: Mellitus Health, Omada Health, Stability Health

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of May 10, 2019 through May 10, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

Statement of Commercial Support

This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP.

1.00 CME / CNE
Medical Education Resources (MER)
Recognizing Progression in Autosomal Dominant Polycystic Kidney Disease: Focus on Primary Care

Recognizing Progression in Autosomal Dominant Polycystic Kidney Disease: Focus on Primary Care

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 CNE Contact Hour
Released: May 10, 2019
Expires: May 10, 2020
1.0 hour to complete

Accredited By

This activity is jointly provided by Medical Education Resources and CMEology.

Media

Internet activity

Target Audience

This certified activity is intended for primary care physicians and other health care providers who have the opportunity to care for patients with ADPKD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Formulate an appropriate and timely diagnosis of ADPKD, including risk of progression
  • Employ strategies to enhance multidisciplinary care across the continuum of ADPKD

Activity Description

This activity will feature a patient at high risk for progression of autosomal dominant polycystic kidney disease (ADPKD) and chronicle her journey through diagnosis, assessment, treatment planning, and monitoring. It will address the role of the primary care provider and will place emphasis on the primary care provider’s approach to initial testing and assessment, as well as recognizing indications for referral to a nephrologist. 

Statement of Educational Need

ADPKD is the most common genetic renal disorder. ADPKD is associated with a diminished quality of life and high health care utilization and costs. The unmet needs associated with ADPKD are among the greatest of all renal diseases. Recent advances in the diagnosis and treatment of ADPKD offer opportunities for timely intervention and better outcomes in patients. However, ADPKD is often identified late, and care may not be effectively coordinated with specialists. Even in those diagnosed with ADPKD in a timely manner, health care providers may not adequately identify patients at risk for rapid ADPKD progression, knowledge that is important to the individualization of management. Ongoing management for ADPKD requires multidisciplinary care and coordination to assess progression, optimize care for renal and nonrenal manifestations, and identify patients appropriate for disease-modifying therapy. This activity is intended to enhance knowledge in the diagnosis, assessment of progression risk, and referral considerations for primary care providers.

Goals (Purpose) of Program 

Health care providers who complete this activity should be able to recognize and assess the risk for disease progression in patients with ADPKD and provide and enhance ongoing management including monitoring and coordination of care.

Faculty

York Pei, MSc, MD, FRCPC
York Pei, MSc, MD, FRCPC
Professor of Medicine
University of Toronto
Staff Nephrologist
Toronto General Hospital
University Health Network
Toronto, Canada

Conflict of Interest Policy/Disclosure Statement

It is the policy of Medical Education Resources (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty has disclosed the following:

York Pei, MSc, MD, FRCPC
Consulting Fees: Otsuka, Sanofi, and Vertex

The following CMEology planners and managers, Beth Goodwin, Rob Lowney, and Dana Ravyn, PhD, MPH, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

The following MER planner and manager, Julie Johnson, PharmD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians and nurses.

Credit Designation
Medical Education Resources designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.  

Continuing Nursing Education

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 1.0 contact hour of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Instructions for Receiving Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.

Requirements for Successful Completion

Upon successfully completing the post-test with a score of 75% or better and the completion of the activity evaluation, the certificate will be made available immediately. 

Statement of Commercial Support

This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

For questions about the certification of this activity, please contact CMEology at: info@cmeology.org.

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 CNE Contact Hour
Released: May 10, 2019
Expires: May 10, 2020
1.0 hour to complete

Accredited By

This activity is jointly provided by Medical Education Resources and CMEology.

Media

Internet activity

Target Audience

This certified activity is intended for primary care physicians and other health care providers who have the opportunity to care for patients with ADPKD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Formulate an appropriate and timely diagnosis of ADPKD, including risk of progression
  • Employ strategies to enhance multidisciplinary care across the continuum of ADPKD

Activity Description

This activity will feature a patient at high risk for progression of autosomal dominant polycystic kidney disease (ADPKD) and chronicle her journey through diagnosis, assessment, treatment planning, and monitoring. It will address the role of the primary care provider and will place emphasis on the primary care provider’s approach to initial testing and assessment, as well as recognizing indications for referral to a nephrologist. 

Statement of Educational Need

ADPKD is the most common genetic renal disorder. ADPKD is associated with a diminished quality of life and high health care utilization and costs. The unmet needs associated with ADPKD are among the greatest of all renal diseases. Recent advances in the diagnosis and treatment of ADPKD offer opportunities for timely intervention and better outcomes in patients. However, ADPKD is often identified late, and care may not be effectively coordinated with specialists. Even in those diagnosed with ADPKD in a timely manner, health care providers may not adequately identify patients at risk for rapid ADPKD progression, knowledge that is important to the individualization of management. Ongoing management for ADPKD requires multidisciplinary care and coordination to assess progression, optimize care for renal and nonrenal manifestations, and identify patients appropriate for disease-modifying therapy. This activity is intended to enhance knowledge in the diagnosis, assessment of progression risk, and referral considerations for primary care providers.

Goals (Purpose) of Program 

Health care providers who complete this activity should be able to recognize and assess the risk for disease progression in patients with ADPKD and provide and enhance ongoing management including monitoring and coordination of care.

Faculty

York Pei, MSc, MD, FRCPC
York Pei, MSc, MD, FRCPC
Professor of Medicine
University of Toronto
Staff Nephrologist
Toronto General Hospital
University Health Network
Toronto, Canada

Conflict of Interest Policy/Disclosure Statement

It is the policy of Medical Education Resources (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty has disclosed the following:

York Pei, MSc, MD, FRCPC
Consulting Fees: Otsuka, Sanofi, and Vertex

The following CMEology planners and managers, Beth Goodwin, Rob Lowney, and Dana Ravyn, PhD, MPH, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

The following MER planner and manager, Julie Johnson, PharmD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians and nurses.

Credit Designation
Medical Education Resources designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.  

Continuing Nursing Education

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 1.0 contact hour of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Instructions for Receiving Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.

Requirements for Successful Completion

Upon successfully completing the post-test with a score of 75% or better and the completion of the activity evaluation, the certificate will be made available immediately. 

Statement of Commercial Support

This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

For questions about the certification of this activity, please contact CMEology at: info@cmeology.org.

0.75 CME / CNE
Purdue University
The Advances in Monoclonal Antibody Therapeutics to Improve Outcomes in Patients with Psoriatic Arthritis and Ankylosing Spondylitis

The Advances in Monoclonal Antibody Therapeutics to Improve Outcomes in Patients with Psoriatic Arthritis and Ankylosing Spondylitis

Start

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit
0.75 CNE Contact Hour
Released: December 10, 2018
Expires: February 24, 2020
45 minutes to complete

Co-provided By

Target Audience

Rheumatologists, primary care physicians, internists, nurse practitioners, nurses, physician assistants, and other healthcare professionals involved in the management of patients with psoriatic arthritis and ankylosing spondylitis.

Learning Objectives

  1. Understand the immunopathology of PsA and AS, as well as early and accurate diagnosing, and disease monitoring
  2. Analyze clinical trial data of current and emerging therapeutic options for the management of PsA and AS
  3. Implement effective and safe treatment plans to improve outcomes in patients with PsA and AS

Activity Description

This CME/CNE activity is derived from content presented at the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) Annual Meeting in Dallas, Texas. The expert faculty, Dr. Alvin F. Wells, will review the characteristics of both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to ensure accurate detection and early diagnosis. Recent guidelines for the treatment and management of PsA and AS patients will be analyzed, along with approved and emerging therapeutic options and their clinical relevance. Dr. Wells will relay best practices for switching therapies and managing the adverse events associated with approved therapies utilizing the interprofessional team. At the conclusion of this activity, clinicians will become better acquainted with optimal treatment strategies to improve their care of psoriatic arthritis and ankylosing spondylitis patients.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with psoriatic arthritis and ankylosing spondylitis.

Agenda

  1. Psoriatic Arthritis and Ankylosing Spondylitis Update: Immunopathology, Accurate Diagnosing and Disease Monitoring
  2. Clinical Analysis of Current and Emerging Therapeutic Options for PsA and AS
  3. Implementing Safe and Effective Treatment Strategies to Improve Outcomes in Patients

Faculty

Alvin F. Wells, MD, PhD
Alvin F. Wells, MD, PhD
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Assistant Professor, Duke University Medical Center
Director, Rheumatology and Immunotherapy Center
Assistant Clinical Professor, Marquette University
Milwaukee, Wisconsin


Disclosures of Conflict of Interest

All faculty AND staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, reviewers, Purdue and AcademicCME staff have nothing to disclose.

Alvin F. Wells, MD, PhD

Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB. Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and AcademicCME, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This program has been approved for 0.75 contact hour.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity is supported by independent educational grants from Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME; Purdue University College of Pharmacy; Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit
0.75 CNE Contact Hour
Released: December 10, 2018
Expires: February 24, 2020
45 minutes to complete

Co-provided By

Target Audience

Rheumatologists, primary care physicians, internists, nurse practitioners, nurses, physician assistants, and other healthcare professionals involved in the management of patients with psoriatic arthritis and ankylosing spondylitis.

Learning Objectives

  1. Understand the immunopathology of PsA and AS, as well as early and accurate diagnosing, and disease monitoring
  2. Analyze clinical trial data of current and emerging therapeutic options for the management of PsA and AS
  3. Implement effective and safe treatment plans to improve outcomes in patients with PsA and AS

Activity Description

This CME/CNE activity is derived from content presented at the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) Annual Meeting in Dallas, Texas. The expert faculty, Dr. Alvin F. Wells, will review the characteristics of both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to ensure accurate detection and early diagnosis. Recent guidelines for the treatment and management of PsA and AS patients will be analyzed, along with approved and emerging therapeutic options and their clinical relevance. Dr. Wells will relay best practices for switching therapies and managing the adverse events associated with approved therapies utilizing the interprofessional team. At the conclusion of this activity, clinicians will become better acquainted with optimal treatment strategies to improve their care of psoriatic arthritis and ankylosing spondylitis patients.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with psoriatic arthritis and ankylosing spondylitis.

Agenda

  1. Psoriatic Arthritis and Ankylosing Spondylitis Update: Immunopathology, Accurate Diagnosing and Disease Monitoring
  2. Clinical Analysis of Current and Emerging Therapeutic Options for PsA and AS
  3. Implementing Safe and Effective Treatment Strategies to Improve Outcomes in Patients

Faculty

Alvin F. Wells, MD, PhD
Alvin F. Wells, MD, PhD
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Assistant Professor, Duke University Medical Center
Director, Rheumatology and Immunotherapy Center
Assistant Clinical Professor, Marquette University
Milwaukee, Wisconsin


Disclosures of Conflict of Interest

All faculty AND staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, reviewers, Purdue and AcademicCME staff have nothing to disclose.

Alvin F. Wells, MD, PhD

Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB. Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and AcademicCME, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This program has been approved for 0.75 contact hour.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity is supported by independent educational grants from Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME; Purdue University College of Pharmacy; Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Pages